The dvm360® cardiology page is home to a plethora of resources involving the latest advancements in diagnosing, managing, and treating cardiology. From expert insights into the latest trends to interviews, videos, podcasts, news, and beyond, find out everything you need to know about cardiology here.
November 22nd 2024
Vetmedin Solution from Boehringer Ingelheim is indicated for treatment of cases caused by myxomatous mitral valve disease or dilated cardiomyopathy and is the first oral solution approved by the FDA for this use in dogs
October 26th 2024
Getting to the heart of the matter: Heart disease and heart failure (Proceedings)
April 1st 2010The most common causes are defective heart muscle, valvular disease, cardiac tamponade, electrical malfunction, heartworms or administration of drugs with profound cardiac effects. In any case, when heart failure results in circulatory collapse and inadequate tissue oxygenation, the patient is said to be in cardiogenic shock. The term "cardiogenic shock" describes a shock syndrome where cardiac output is reduced as a direct result of heart failure.
Feline heartworm disease (Proceedings)
April 1st 2010Feline heartworm disease is more common than previously believed, often fatal and completely preventable. It is now estimated that 26% of cats may be infected with heartworm disease. This is very significant especially when compared to 5% who are FeLV positive and 6% who have FIV.
Managing chronic valvular disease (Proceedings)
April 1st 2010CDVD is the most common cause of cardiac disability in dogs. The disease process is best described as myxomatous degeneration of the heart valves wherein the integrity of the valves is compromised often resulting in valvular insufficiencies.
Therapy of new onset and refractory heart failure (Proceedings)
April 1st 2010Diuretics (reduction in preload), vasodilators (reduction in preload or afterload), angiotensin converting-enzyme inhibitors (reduce afterload and preload, reduce fibrosis), and positive inotropic drugs (increase contractility, may reduce regurgitant volume) all have demonstrated the capacity to lessen the severity of mitral regurgitation and dilated cardiomyopathy under certain conditions.
Managing dilated cardiomyopathy (Proceedings)
April 1st 2010The cause(s) of dilated cardiomyopathy (DCM) in dogs is (are) unknown. Some of the proposed causes of DCM include: genetic defect(s), viral infection, microvascular spasm, chemical toxin(s), dietary deficiency, and immune-mediated processes.
Congenital heart disease (Proceedings)
April 1st 2010The primary objectives of the cardiovascular evaluation for animals with congenital heart disease are to define the nature and severity of the anatomic defect present. Familiarity with the available therapeutic options, their efficacy and limitations is necessary before an accurate prognosis can be offered to the owner.
Hot Literature: New guidelines for diagnosing and treating chronic valvular heart disease in dogs
March 1st 2010To more objectively categorize patients and to complement the current classification system, the American College of Veterinary Internal Medicine (ACVIM) Specialty of Cardiology consensus panel has developed a set of guidelines for the diagnosis and treatment of CVHD.
Essentials of echocardiography (Proceedings)
November 1st 2009Echocardiography has emerged as the most valuable non-invasive tool for evaluation of cardiac structure, function, blood flow patterns, and has greatly diminished the need for diagnostic cardiac catheterizations and angiocardiography in many cases.
Pericardial effusion: causes and clinical outcomes in dogs (Proceedings)
November 1st 2009Pericardial effusion is a fairly common acquired heart disease in dogs, and prevalence has been reported to be 0.43% (or 1 dog per 233 cases) of dogs presenting to a referral veterinary hospital, and accounts for approximately 7% of dogs with clinical signs of cardiac disease.